IVA News and Press, Inventiva S.A. From 03/30/23

2023-03-30 13:19:05 ET Inventiva S.A. (IVA) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman &#x...

2023-03-29 16:08:56 ET Inventiva press release ( NASDAQ: IVA ): FY GAAP EPS of -€1.31 misses by €0.02 . Revenue of €12.18M (+190.7% Y/Y) misses by €0.44M . Other income amounted to €6.6 million for the full year 2022, as ...

Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis, announced the receipt of the €25M payment under the first tranche of the unsecured loan agreement executed with the Eur...

Inventiva ( NASDAQ: IVA ) ( OTCPK:IVEVF ) said AbbVie ( NYSE: ABBV ) has decided to stop the development of cedirogant (ABBV-157) to treat autoimmune diseases after analysis of a nonclinical toxicology study. In 2012, the two companies entered a collab...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ventdusud / Shutterstock.com We’re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! There’s major marijuana news moving stocks thi...

Summary Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharm, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from France’s Inventiva in a $307 million deal. Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acq...

Inventiva S.A. (IVA) Q2 2022 Earnings Conference Call September 22, 2022, 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial ...

Inventiva press release ( NASDAQ: IVA ): 1H GAAP EPS of -$0.72. Revenue of $67K (-51.8% Y/Y). For further details see: Inventiva GAAP EPS of -$0.72, revenue of $67M

France-based clinical-stage biopharma Inventiva ( NASDAQ: IVA ) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. ...

Inventiva press release (NASDAQ:IVA): Cash position at €80.5m as of March 31, 2022 The Group did not generate any revenue in Q1 2022 Signature of a €50 million bullet credit facility agreement with the European Investment Bank For further details see: Inventiva r...